Myriad, Google, Sturgis, HMV, EFF: Intellectual Property

In the wake of Myriad Genetics Inc.’s infringement suit against a competitor that said it would offer breast and ovarian cancer tests, the head of the U.S. Senate’s Committee on the Judiciary has called for mandatory licensing of the Utah-based company’s tests.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.